Lymphoma (includes NHL, HL, CNS Lymphoma)

9 Deaths Are Linked to Rare Cancer From Breast Implants

(New York Times) Mar 21, 2017 - A rare cancer first linked to breast implants in 2011 has now been associated with nine deaths, the Food and Drug Administration said Tuesday.

read article

March 29, 2017: Oncologic Drugs Advisory Committee Meeting Announcement

(FDA.gov) Mar 16, 2017 - Agenda: During the morning session of March 29, 2017, the committee will discuss biologics license application (BLA) 761064, rituximab/hyaluronidase injection for subcutaneous use, submitted by Genentech, Inc.

read press release

Threshold Pharmaceuticals, Molecular Templates to Merge

(Genetic Engineering & Biotechnology News) Mar 17, 2017 - Molecular Templates will merge with a wholly owned subsidiary of Threshold Pharmaceuticals in an all-stock deal designed to create a combined developer of novel cancer treatments, the companies said today.

read article (free registration required)

The Leukemia & Lymphoma Society Appoints Dr. Gwen Nichols as Chief Medical Officer

(LLS.org) Mar 16, 2017 - The Leukemia & Lymphoma Society (LLS), the world’s largest voluntary health agency dedicated to fighting blood cancer, announced it has appointed Gwen Nichols, M.D., chief medical officer (CMO).

read press release

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy

(Merck) Mar 14, 2017 - Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after three or more prior lines of therapy.

read corporate press release

NICE Asks for More Data on Opdivo

(Pharma Times [UK]) Mar 15, 2017 - The National Institute for Health and Care Excellence has published draft guidelines recommending that Bristol Myers-Squibb provide more information on Opdivo’s effectiveness for treating classical Hodgkin lymphoma.

read article

Monsanto Weed Killer Roundup Faces New Doubts on Safety in Unsealed Documents

(New York Times) Mar 14, 2017 - The reputation of Roundup, whose active ingredient is the world’s most widely used weed killer, took a hit on Tuesday when a federal court unsealed documents raising questions about its safety and the research practices of its manufacturer, the chemical giant Monsanto.

read article

FDA OKs Pembrolizumab for Classical Hodgkin Lymphoma

(Medscape Medical News) Mar 14, 2017 - The US Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda, Merck) for children and adults who have classical Hodgkin lymphoma (cHL) that has resisted treatment or relapsed after three or more prior lines of therapy.

read article (free registration required)

Kite Pharma Highlights Publication From the National Cancer Institute Demonstrating Durable Complete Remissions in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy and Anti-CD19 CAR T-Cell Therapy

(Yahoo! Finance) Mar 14, 2017 - Kite Pharma, Inc. today highlighted the publication of results in the Journal of Clinical Oncology from a National Cancer Institute (NCI) study of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).

read article

Hodgkin Lymphoma Survivors At High Risk Of Second Cancers

(ICR [UK]) Mar 13, 2017 - Patients who are cured of Hodgkin lymphoma are at a high risk of developing a second type of cancer, particularly if they have a family history of the disease, a major new study reports.

read article

Possible Cures. Mystery Deaths. Daunting Costs. Can CAR-T Be Tamed?

(Xconomy National) Mar 13, 2017 - So-called CAR-T treatments, administered experimentally in clinical trials, have helped dozens of patients with otherwise untreatable blood cancers.

read article

EU Nod for Actelion’s Rare Immune System Cancer Drug

(PharmaTimes [UK]) Mar 8, 2017 - Actelion has bagged European Union Approval for Ledaga, its treatment for mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL), a rare potentially life-threatening immune system cancer that appears in the skin.

read article

Total Skin Electron Radiation Used to Treat Rare Cancer

(University of Wisconsin Health [Madison, WI]) Mar 1, 2017 - For patients with early-stage mycosis fungoides, a form of cutaneous T-cell lymphoma, total skin electron radiation therapy can provide long-term, symptom-free survival.

read press release

CAR-T is Headed To The FDA. Now What?

(STAT Plus) Feb 28, 2017 - Today’s news from Kite Pharma — positive six-month data for patients with severe lymphoma — stokes a blockbuster race that also involves Novartis and Juno Therapeutics, with each angling to carve out a space in what analysts say will be a multibillion-dollar market.

read article (paid subscription required)

Gene Therapy "Seems Extraordinary" at Fighting Blood Cancer in Study, Experts Say

(ABC News/Associated Press) Feb 28, 2017 - An experimental gene therapy that turns a patient’s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.

read article

Kite Announces Positive Topline Primary Results of Axicabtagene Ciloleucel from First Pivotal CAR-T Trial in Patients with Aggressive Non-Hodgkin Lymphoma

(Kite Pharma) Feb 28, 2017 - Kite Pharma, Inc., today announced positive data from the primary analysis of ZUMA-1 for its lead CAR-T candidate, axicabtagene ciloleucel (previously referred to as KTE-C19), in patients with chemorefractory aggressive B-cell non-Hodgkin lymphoma (NHL).

read corporate press release

Mundipharma to Launch Mabthera Biosimilar In EU Markets

(PharmaTimes [UK]) Feb 23, 2017 - Mundipharma is gearing up to launch biosimilar Truxima in seven European markets for the treatment of certain cancers and inflammatory conditions, after Celltrion bagged a regulatory approval for the drug.

read article

Standing Up To The Test Of Time: Two Cancer Drugs That Could Survive A Hobbled FDA

(Forbes) Dec 7, 2016 - If the Food and Drug Administration gets gutted, and pressured by politicians to lower its standards to allow more drugs on the market more quickly, how would that change the pharmaceutical business?

read article

How is European Immuno-Oncology Fighting Blood Cancer?

(labiotech.eu) Dec 6, 2016 - From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year’s edition of the American Society of Hematology (ASH) annual meeting features immuno-oncology therapies developed by the best European biotechs, with Novartis taking the lead in the CAR-T field.

read article

Psychosocial Factors Associated With High Readmission Rates Longer Hospital Stays

(OSUCCC - The James) Dec 5, 2016 - A new study shows that psychosocial risk factors that impact a person’s ability to cope with chronic stress are associated with significantly higher readmission rates and longer hospital stays among blood cancer patients undergoing hematopoietic stem cell transplantation (HSCT).

read press release
Next Page